Sutro Biopharma (NASDAQ:STRO) PT Set at $18.00 by HC Wainwright

Sutro Biopharma (NASDAQ:STRO) has been given a $18.00 target price by investment analysts at HC Wainwright in a note issued to investors on Monday, Stock Target Advisor reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s target price suggests a potential upside of 54.24% from the stock’s previous close.

STRO has been the topic of several other research reports. Zacks Investment Research raised Sutro Biopharma from a “sell” rating to a “hold” rating in a research report on Thursday, June 13th. Wedbush increased their target price on Sutro Biopharma from $20.00 to $22.00 and gave the company an “outperform” rating in a research report on Monday, March 4th. Cowen reaffirmed a “buy” rating on shares of Sutro Biopharma in a research report on Sunday, June 16th. Finally, ValuEngine cut Sutro Biopharma from a “buy” rating to a “hold” rating in a research report on Wednesday, May 1st. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the stock. Sutro Biopharma presently has an average rating of “Buy” and a consensus target price of $22.75.

Shares of NASDAQ:STRO opened at $11.67 on Monday. The company has a market capitalization of $272.13 million and a PE ratio of -1.90. The business has a 50 day moving average price of $11.09. Sutro Biopharma has a 52-week low of $8.50 and a 52-week high of $15.90.

Hedge funds and other institutional investors have recently made changes to their positions in the business. American International Group Inc. bought a new stake in Sutro Biopharma during the 4th quarter valued at $38,000. Deutsche Bank AG purchased a new stake in shares of Sutro Biopharma during the 4th quarter valued at $87,000. Spark Investment Management LLC purchased a new stake in shares of Sutro Biopharma during the 1st quarter valued at $168,000. SG Americas Securities LLC purchased a new stake in shares of Sutro Biopharma during the 4th quarter valued at $169,000. Finally, Geode Capital Management LLC purchased a new stake in shares of Sutro Biopharma during the 4th quarter valued at $456,000. 49.00% of the stock is currently owned by institutional investors and hedge funds.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers.

Featured Article: What is Compound Interest?

Analyst Recommendations for Sutro Biopharma (NASDAQ:STRO)

Receive News & Ratings for Sutro Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sutro Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit